Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613222 · ClinicalTrials.gov registry record · NA
SpO2 System Accuracy Testing With Different Sensors
A NA study, sponsored by GE Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT01613222: Completed NA study, sponsored by GE Healthcare.
NCT01613222 is a NA study that has completed, run by GE Healthcare. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01613222, a NA study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
A study to test the accuracy of SpO2 sensors with various patient monitors, co-oximeters, and modules.
Primary Outcome
The Accuracy Root Mean Square (ARMS) calculation is used to measure accuracy of the test SpO2 device compared to reference SpO2 device. A scatterplot is created with the forehead sensor saturation on the y-axis and the measured blood saturation on the x-axis. The line of identity is drawn representing the ideal points, meaning that the forehead sensor saturation is always the same as the blood saturation. The dispersion of the actual data points around the line of identity can be measured using
Interventions
- DEVICE Pulse oximetry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2013-02-15 |
| Phase | NA |
What the finished NCT01613222 record still lists
NCT01613222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Pulse oximetry is the first listed.
NCT01613222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01613222 about?
NCT01613222 is a clinical study titled "SpO2 System Accuracy Testing With Different Sensors". A study to test the accuracy of SpO2 sensors with various patient monitors, co-oximeters, and modules.
What is the current status of trial NCT01613222?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-06-19. Estimated completion is 2013-02-15.
What interventions are being tested in trial NCT01613222?
The interventions under investigation include: Pulse oximetry (DEVICE).
Who is sponsoring clinical trial NCT01613222?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01613222's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI